Recent 8-K filings for HEPA

• October 9, 2026, 4:30 PM ET M&A materiality 0.95 neutral item 1.01item 2.01item 9.01item 3.02item 5.02 ◈ executive_change ×2

  Hepion Pharmaceuticals acquires Gravitas Life Sciences for $2M cash plus 25M shares and names new CEO and CFO

  Hepion acquired all Gravitas Life Sciences membership interests for $2,000,000 cash plus 25,000,000 shares (valued at $2,250,000) and an extra $135,000 payment.

• September 28, 2026, 6:30 AM ET regulatory materiality 0.70 negative item 4.01item 9.01

  Hepion Pharmaceuticals replaces Grassi with RRBB as auditor amid going-concern doubt and material weaknesses

  Hepion's audit committee approved dismissing Grassi & Co., CPAs, P.C. and engaging Rosenberg Rich Baker Berman P.A. as independent auditor on Sept. 21, 2026.

• August 4, 2026, 9:17 AM ET other material materiality 0.70 negative item 1.01item 3.02item 9.01

  Hepion Pharmaceuticals raises $3.1M in private placement of 61.1M shares and warrants

  Gross proceeds of $3,055,000 from sale of 61,100,000 shares at $0.05 per share.

• March 18, 2026, 7:59 PM ET leadership materiality 0.60 neutral item 5.02

  Hepion Pharma CEO Kaouthar Lbiati resigns; Gary Stetz named interim CEO

  CEO Dr. Kaouthar Lbiati resigned effective March 16, 2026, for personal reasons.

• January 15, 2026, 6:59 PM ET leadership materiality 0.65 neutral item 5.02

  Hepion Pharmaceuticals names Kaouthar Lbiati CEO effective Jan 8, 2026; salary $350K

  Dr. Kaouthar Lbiati appointed CEO effective Jan 8, 2026, per Board approval on Jan 13, 2026.

• June 30, 2025, 7:59 PM ET leadership materiality 0.65 negative item 5.02

  Hepion Pharmaceuticals CFO John Brancaccio resigns; interim CFO named

  John Brancaccio resigned as CFO and director effective June 30, 2025, for personal reasons.

• June 12, 2025, 7:59 PM ET other material materiality 0.60 negative item 5.07

  Hepion shareholders reject reverse stock split amendment at 2025 annual meeting

  Reverse stock split proposal (1:5 to 1:20) failed with 2.25M for, 3.70M against; not approved.

• June 9, 2025, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 ◈ executive_change

  Hepion appoints director Kaouthar Lbiati as interim CEO effective June 16

  Dr. Kaouthar Lbiati, a board member since June 2022, appointed interim CEO effective June 16, 2025.

• May 30, 2025, 7:59 PM ET other material materiality 0.80 negative item 1.01

  Hepion sells Rencofilstat assets to Panetta for nominal fee; stockholders get CVR milestones

  Sold all patent assets, knowhow, clinical data, and drug product for Rencofilstat to Panetta Partners for nominal amount.

• May 12, 2025, 7:59 PM ET other material materiality 0.90 negative item 3.01item 9.01 ◈ Listing & Compliance Notices ×2

  Hepion delisted from Nasdaq; pivots to diagnostics via New Day license

  Received Nasdaq delisting notice for failing to maintain $1.00 bid price and being deemed a public shell; trading suspended May 13, 2025.

• April 17, 2025, 7:59 PM ET regulatory materiality 0.85 negative item 3.01 ◈ Listing & Compliance Notices

  Nasdaq deems Hepion a 'public shell' as additional delisting basis; hearing April 29

  Received Nasdaq notice on April 15, 2025, alleging company is a 'public shell' and continued listing unwarranted.

• March 20, 2025, 7:59 PM ET regulatory materiality 0.80 negative item 3.01 ◈ Listing & Compliance Notices

  Hepion receives Nasdaq delisting notice as bid price falls below $0.10 for 10 days

  Stock closed below $0.10 for 10 consecutive business days triggering the Low Priced Stocks Rule.

• March 10, 2025, 7:59 PM ET other material materiality 0.65 neutral item 5.07

  Hepion shareholders approve reverse stock split (1:10-1:50) at annual meeting

  All four director nominees elected (Brancaccio, Block, Lbiati, Purcell) with majority 'For' votes.

• January 15, 2025, 6:59 PM ET regulatory materiality 0.60 negative item 3.01 ◈ Listing & Compliance Notices ×2

  Hepion Pharma receives Nasdaq delisting notice for failure to hold annual meeting; 45 days to submit compliance plan

  Notice dated January 14, 2025 from Nasdaq for failing to hold annual shareholders' meeting within 12 months of fiscal year end.

• December 11, 2024, 6:59 PM ET other material materiality 0.80 negative item 1.02item 8.01item 9.01

  Hepion terminates merger with Pharma Two B; special meeting cancelled

  Merger Agreement with Pharma Two B Ltd. terminated mutually on Dec 10, 2024.

• November 21, 2024, 6:59 PM ET regulatory materiality 0.75 negative item 3.01

  Hepion Pharma receives Nasdaq delisting notice due to stockholder deficit and failure to meet listing alternatives

  Stockholders' deficit of ($406,685) as of Sept 30, 2024 triggers Nasdaq Listing Rule non-compliance.

• September 5, 2024, 7:59 PM ET regulatory materiality 0.70 negative item 3.01

  Hepion Pharmaceuticals receives Nasdaq deficiency notice for bid price below $1.00

  Notice received Sept. 3, 2024; bid price below $1.00 for 30 consecutive business days.

• August 7, 2024, 7:59 PM ET leadership materiality 0.70 negative item 5.02 ◈ executive_change ×2

  Hepion Pharma's interim CEO/CFO resigns; executive chairman takes over

  John Cavan departed as interim CEO and CFO on August 5, 2024 for personal reasons.

• July 22, 2024, 7:59 PM ET M&A materiality 0.80 neutral item 1.01item 2.03item 3.02item 5.02item 7.01item 8.01item 9.01

  Hepion Pharmaceuticals enters definitive merger agreement with Pharma Two B Ltd., expects Q4 2024 close

  Hepion will merge with Pharma Two B Ltd.; existing Hepion shareholders receive ordinary shares of Parent.

• February 16, 2024, 6:59 PM ET other material materiality 0.60 negative item 1.01item 3.02item 9.01

  Hepion raises $2.06M via warrant inducement, reduces exercise prices and issues new warrants

  Holders of 980,393 Series B warrants will exercise at reduced price of $2.10/share, raising ~$2.06M gross proceeds.

• January 3, 2024, 6:59 PM ET other material materiality 0.60 negative item 4.01item 9.01 ◈ Auditor Changes ×2

  Hepion Pharmaceuticals dismisses BDO, appoints Grassi as new auditor

  BDO dismissed as independent auditor effective Jan 1, 2024; Grassi Advisors engaged to audit FY 2023 financials.

• December 7, 2023, 6:59 PM ET leadership materiality 0.75 negative item 5.02item 8.01item 9.01 ◈ executive_change ×3

  Hepion CEO resigns, interim CEO named; restructuring plan to cut costs 60%

  Dr. Robert Foster resigns as CEO and director for personal reasons, effective immediately.

• October 3, 2023, 7:59 PM ET other material materiality 0.65 neutral item 1.01item 3.02item 8.01item 9.01 ◈ Material Agreements

  Hepion Pharmaceuticals raises $5.0M in registered direct offering with warrants

  Gross proceeds $5.0M from sale of 980,393 shares (or equivalents) at $5.10/share plus warrants.

• July 21, 2023, 7:59 PM ET other material materiality 0.65 neutral item 1.01item 9.01 ◈ Material Agreements

  Hepion Pharmaceuticals enters $24M ATM equity offering with Cantor Fitzgerald

  ATM sales agreement with Cantor Fitzgerald allows Hepion to sell up to $24M of common stock at market prices.

• May 22, 2023, 7:59 PM ET other material materiality 0.80 positive item 7.01item 8.01item 9.01

  Hepion Phase 2 ALTITUDE-NASH trial meets primary endpoint with rencofilstat 225 mg improving liver function

  Phase 2 trial met primary endpoint: 225 mg rencofilstat reduced DSI by 1.62 units (p<0.05) and SHUNT by 2.8% (p<0.05).

• November 9, 2022, 6:59 PM ET other material materiality 0.80 neutral item 1.01item 3.02item 3.03item 5.03item 8.01item 9.01 ◈ Material Agreements

  Hepion Pharmaceuticals Raises $20M via Private Placement of Convertible Preferred Stock

  Offering includes 1,900,000 Series F and 100,000 Series G shares at $9.50 each.

Executive changes

Materiality & sentiment trend

Max materiality 0.95 · Median 0.60 · Most common event other_material

1 positive 18 negative 31 neutral

source · HEPA on sec.gov